1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Peptide Therapeutics Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Peptide Therapeutics Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Growing Investments on Peptide Therapeutics
5.2 Market Opportunities
- 5.2.1 Operational Limitations of Peptides
5.3 Future Trends
- 5.3.1 Emphasis on Automatic Peptide Synthesis
5.4 Impact of Drivers and Restraints
6. Europe Peptide Therapeutics Market Regional Analysis
6.1 Europe Peptide Therapeutics Market Overview
6.2 Europe Peptide Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 Europe Peptide Therapeutics Market Forecast Analysis
7. Europe Peptide Therapeutics Market Analysis – by Type
7.1 Generic
- 7.1.1 Overview
- 7.1.2 Generic: Europe Peptide Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Innovative
- 7.2.1 Overview
- 7.2.2 Innovative: Europe Peptide Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Peptide Therapeutics Market Analysis – by Route of Administration
8.1 Parenteral
- 8.1.1 Overview
- 8.1.2 Parenteral: Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Oral
- 8.2.1 Overview
- 8.2.2 Oral: Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Mucosal
- 8.3.1 Overview
- 8.3.2 Mucosal: Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Pulmonary
- 8.4.1 Overview
- 8.4.2 Pulmonary: Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9. Europe Peptide Therapeutics Market Analysis – by Synthesis Technology
9.1 Solid Phase Peptide Synthesis
- 9.1.1 Overview
- 9.1.2 Pulmonary: Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Liquid Phase Peptide Synthesis
- 9.2.1 Overview
- 9.2.2 Pulmonary: Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Hybrid Technology
- 9.3.1 Overview
- 9.3.2 Pulmonary: Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
10. Europe Peptide Therapeutics Market – Europe Analysis
10.1 Europe
- 10.1.1 Europe Peptide Therapeutics Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.1.1.1 Europe Peptide Therapeutics Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 UK:
Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.1.1 UK: Europe Peptide Therapeutics Market Breakdown, by Type
- 10.1.1.1.2 UK: Europe Peptide Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.1.3 UK: Europe Peptide Therapeutics Market Breakdown, by Synthesis Technology
- 10.1.1.2 Germany:
Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.2.1 Germany: Europe Peptide Therapeutics Market Breakdown, by Type
- 10.1.1.2.2 Germany: Europe Peptide Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.2.3 Germany: Europe Peptide Therapeutics Market Breakdown, by Synthesis Technology
- 10.1.1.3 France:
Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.3.1 France: Europe Peptide Therapeutics Market Breakdown, by Type
- 10.1.1.3.2 France: Europe Peptide Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.3.3 France: Europe Peptide Therapeutics Market Breakdown, by Synthesis Technology
- 10.1.1.4 Russia:
Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.4.1 Russia: Europe Peptide Therapeutics Market Breakdown, by Type
- 10.1.1.4.2 Russia: Europe Peptide Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.4.3 Russia: Europe Peptide Therapeutics Market Breakdown, by Synthesis Technology
- 10.1.1.5 Italy:
Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.5.1 Italy: Europe Peptide Therapeutics Market Breakdown, by Type
- 10.1.1.5.2 Italy: Europe Peptide Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.5.3 Italy: Europe Peptide Therapeutics Market Breakdown, by Synthesis Technology
- 10.1.1.6 Rest of Europe:
Europe Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.6.1 Rest of Europe: Europe Peptide Therapeutics Market Breakdown, by Type
- 10.1.1.6.2 Rest of Europe: Europe Peptide Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.6.3 Rest of Europe: Europe Peptide Therapeutics Market Breakdown, by Synthesis Technology
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Europe Peptide Therapeutics Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Amgen Inc.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Eli Lilly and Company
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 EVER Pharma GmbH
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Polypeptide Group
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 AstraZeneca
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Bristol-Myers Squibb Company
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 GlaxoSmithKline plc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Novo Nordisk A/S
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Sanofi
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights